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ABSTRACT 
Objective  
Although not typical of Parkinson’s disease (PD), caudate dopaminergic dysfunction can occur in 
early stages of the disease. However, its frequency and longitudinal implications in large cohorts of 
recently diagnosed patients remain to be established. We investigated the occurrence of caudate 
dopaminergic dysfunction in the very early phases of PD (<2 years from diagnosis) using 123I-FP-
CIT SPECT and determined whether it was associated with the presence or subsequent 
development of cognitive impairment, depression, sleep and gait problems.  
 
Methods 
PD patients and healthy controls were identified from the Parkinson’s Progression Markers 
Initiative database. We defined a clinically significant caudate dysfunction as 123I-FP-CIT binding 
<-2 standard deviations compared to the controls’ mean and categorised three groups accordingly 
(no reduction, unilateral reduction, bilateral reduction). All statistical analyses were adjusted for 
mean putamen binding. 
 
Results  
At baseline, 51.6% of 397 patients had normal caudate DAT binding, 26.0% had unilateral caudate 
involvement, 22.4% had bilaterally impaired caudate.   
Compared to those with a baseline normal caudate function, at the four-year follow-up patients with 
a baseline bilateral caudate involvement showed a higher frequency of cognitive impairment 
(p<0.001) and depression (p<0.001), and worse cognitive (p<0.001), depression (<0.05) and gait 
(<0.001) ratings. Significant caudate involvement was observed in 83.9% of the population after 
four years (unilateral 22.5%, bilateral 66.5%). 
 
Conclusions  
Early significant caudate dopaminergic denervation was found in half of the cases in the PPMI 
series. Baseline bilateral caudate involvement was associated with increased risk of developing 
cognitive impairment, depression and gait problems over the next four years. 
 
 
 
 
  
INTRODUCTION 
Caudate dopaminergic dysfunction is commonly seen in patients with established and advanced 
Parkinson’s disease (PD) and plays a role in the pathophysiology of parkinsonian symptoms such as 
cognitive impairment,1–7 depression,8 REM sleep behaviour disorder (RBD),9 and gait 
problems.10,11 Conversely, both post-mortem and in vivo imaging studies suggest that caudate 
function is preserved in the early stages of PD. In fact, dopaminergic neurons of the substantia nigra 
pars compacta (SNc) degenerate in a selective pattern, with earliest and most severe loss occurring 
in the ventral tier projecting to the posterior putamen and tail of caudate, followed by the dorsal tier 
projecting to the head of caudate nucleus, the globus pallidus, and the neocortex.12,13 Neuroimaging 
studies using SPECT and PET dopaminergic tracers14–16 confirm that the dopaminergic deficit 
within the striatum is unevenly distributed with a more severe involvement of the posterior putamen 
and a relative sparing of the head of caudate nucleus. This asymmetrical posterior-to-anterior 
gradient of dopaminergic dysfunction is present from early disease stages and does not change 
substantially with disease progression.17,18  
However, the occurrence of caudate involvement in the early stages of the disease and the clinical 
implications of such early caudate dysfunction (i.e. the current or subsequent manifestation of 
cognitive impairment, depression, RBD, gait problems) have not been fully investigated in large 
cohorts. 
 
MATERIALS AND METHODS 
Study design and participants 
In this longitudinal study, we analysed clinical ratings and 123I-FP-CIT SPECT data from a cohort 
of early stage PD patients and healthy controls (HCs) recruited in the Parkinson’s Progression 
Marker Initiative (PPMI), an ongoing multicentre, longitudinal study aiming to identify biomarkers 
of PD progression. PD patients were required to have a clinical diagnosis for two years or less, be 
untreated and show evidence of striatal dopamine transporter deficit on SPECT imaging (study 
protocol available at https://www.ppmi-info.org/study-design/research-documents-and-sops/).19 
We performed three main analyses: (i) we evaluated caudate 123I-FP-CIT binding at baseline and 
follow-up in PD patients and HCs. PD patients were categorised in three subgroups according to 
their baseline caudate binding compared to HCs (no reduction, unilateral reduction, bilateral 
reduction); (ii) we assessed whether these three PD subgroups showed different baseline 
manifestations in terms of cognitive impairment, depression, RBD, and gait problems; (iii) we 
investigated  whether the initial pattern of caudate dopaminergic dysfunction was able to predict 
worse outcomes and increased risk of developing cognitive, mood, sleep and gait problems at four-
year follow-up. 
At the time of our analysis, we retrieved 405 PD patients and 177 HCs whose baseline assessments, 
including SPECT scan, motor and non-motor scores were available in the PPMI database 
(http://www.ppmi-info.org/data). At four-year follow-up, clinical assessments were available for 
328 patients and SPECT imaging for 267. Four-year follow-up clinical assessments were available 
for 151 HCs; no follow-up SPECT imaging was provided for HCs in the PPMI. 
123I-FP-CIT SPECT striatal specific binding ratios (SBRs) and demographics and clinical variables 
at baseline and four-year follow-up of all the study participants were downloaded from the PPMI 
database on the 15th May 2018.  
 
Clinical Evaluations 
PD motor disability was assessed with the Movement Disorder Society Unified Parkinson’s Disease 
Rating Scale (MDS-UPDRS) and the Hoehn&Yahr scale. To assess differences in gait impairment 
between groups at baseline and four-year follow-up, we calculated an index of gait severity by 
using the product of the patient’s self-reported walking and balance score (sub-item 2.12, MDS-
UPDRS part II) and the freezing score (2.13, MDS-UPDRS part II) (Maximum score=16). All 
scores were collected in the OFF state. 
Scores of the following non-motor scales were also obtained: Montreal Cognitive Assessment 
(MoCA), the 15-item Geriatric Depression Scale (GDS) and RBD Screening Questionnaire 
(RBDSQ). For each patient, one point was added to the MoCA unadjusted score of those who had 
twelve years of education or less, as indicated in the test original validation study20 and in the PPMI 
protocol. A GDS score 5 was considered diagnostic for the presence of significant depressive 
features.21 
Study participants were allocated to one of three cognitive categories (normal cognition, mild 
cognitive impairment, dementia) based on recommended criteria for dementia22 and mild cognitive 
impairment (MCI)23 and as outlined in the PPMI protocol (see Supplementary Material-Section 
1) 
Lastly, the final clinical diagnosis at four-year follow-up based on clinical judgment of the 
investigator was recorded to determine if the patient’s diagnosis had changed compared to baseline.  
Eight patients initially diagnosed as idiopathic PD were re-diagnosed as a form of atypical 
parkinsonism: four had their diagnosis switched to Multiple system atrophy (MSA), three to 
Dementia with Lewy bodies (DLB), one to Corticobasal degeneration (CBD). These patients were 
excluded from the main analysis and their neuroimaging features analysed separately. Therefore, a 
total of 397 patients at baseline and 323 patients at follow-up were included in the main analysis. 
 
123I-FP-CIT SPECT Imaging protocol 
A detailed description is provided in Supplementary Material-Section 2. Briefly, all subjects 
underwent 123I-FP-CIT SPECT scans during the screening visit and at follow-ups (PD patients only) 
at their respective PPMI imaging centre, where standardized imaging protocols were used. Raw 
SPECT data were transferred back to the Institute for Neurodegenerative Disorders, New Haven, 
Connecticut (PPMI Imaging Core), for processing and calculations of SBRs. Upon transfer to the 
PPMI imaging core, images were processed and normalized to standard Montreal Neurologic 
Institute (MNI) space so that all scans were in the same anatomical alignment. Next, the transaxial 
slice with the highest striatal binding was identified and the eight contiguous slices with highest 
striatal signal were then averaged to generate a single transaxial image. Regions of interest (ROI) 
were then placed to sample the left (area 240 mm2) and right caudate (area 244 mm2), the left (area 
412 mm2) and right putamen (area 408 mm2), and the occipital cortex (reference tissue, area 4500 
mm2).  
Count densities for each region were extracted and used to calculate SBRs for each of the four 
striatal subregions.  
𝑆𝐵𝑅 = (𝑡𝑎𝑟𝑔𝑒𝑡 𝑟𝑒𝑔𝑖𝑜𝑛/𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑟𝑒𝑔𝑖𝑜𝑛)  − 1. 
SBRs of caudate and putamen of each participant were downloaded from the PPMI database. SBR 
measures were rounded to the first two decimals. Mean caudate DAT SBRSD (95% CI) in 
controls was 2.960.60 (2.88–3.06). The caudate signal was considered to be significantly abnormal 
in PD patients if its level of 123I-FP-CIT binding fell two standard deviations or more below 
the mean caudate binding of HCs at baseline (mean -2SDs=1.76). Three PD subgroups were then 
categorised as follows: those with no reduced 123I-FP-CIT binding in either caudate (PD-NC), those 
with reduced caudate binding in one caudate only (PD-UC) and those with bilaterally reduced 
caudate binding (PD-BC). Accordingly, we defined significant early caudate dysfunction a caudate 
123I-FP-CIT binding <-2 SDs compared to the controls’ mean at the baseline SPECT acquisition. 
 
Statistical analysis 
Statistical interrogations were performed using the Statistical Package for the Social Sciences 
version 21 (SPSS 21). For descriptive analyses means and standard deviations were computed for 
continuous variables, and the χ2 test was used for categorical variables. Data were assessed for a 
normal distribution using Kolmogorov-Smirnov test. MoCA, GDS and RDBSQ ratings were 
normally distributed, gait index scores showed a non-normal distribution. 
At baseline, between-group differences were investigated using ANOVA followed by a post hoc 
test with Bonferroni correction for normally distributed data. At follow-up, between-group 
differences of normally-distributed variables were investigated through ANCOVA followed by a 
post hoc test with Bonferroni correction, holding putamen, age and years of education as covariates 
where appropriate. Non-normally distributed data were explored through a Kruskal Wallis test 
followed by Mann-Whitney U tests, and p-values were adjusted through a Bonferroni correction. 
All multiple comparisons for categorical data at baseline and follow-up were assessed through a χ2 
omnibus test followed by a standardized residuals analysis; p-values were adjusted through a 
Bonferroni correction. 
 
RESULTS 
Baseline  
The baseline analysis included 397 PD patients (men/women: 258/139, age: 61.7±9.7 years) and 
177 HCs (men/women: 116/61, age: 60.95±11.2 years). In 397 PD patients, normal 123I-FP-CIT 
binding in either caudate nuclei (PD-NC) was noted in 51.6% (n=205) of patients, 26.0% (n=103) 
had reduced tracer binding in one caudate only (PD-UC), and 22.4% (n=89) had reduced tracer 
binding in both caudate nuclei (PD-BC) (Figure 1A). No significant differences were found in the 
left/right distribution of the most affected caudate across the three PD subgroups. At baseline all 
patients with a unilateral or bilateral caudate DAT reduction also had either a unilateral or bilateral 
putaminal reduction. More details about caudate and putamen involvement in individual patients are 
reported in Supplementary Tables 1 and 2. Mean putamen specific binding ratio was significantly 
different across the three groups (F=90.003, p<0.001), with PD-BC significantly lower than the 
other two groups, and PD-UC significantly lower than PD-NC. However, the caudate/putamen 
ratio, which provides an index of the posterior-to-anterior dopaminergic loss gradient, was not 
significantly different across the three groups. Age across the three PD subgroups and HCs was 
significantly different (F=3.657, p<0.05), with the PD-BC group being older (64.46±8.13 years) 
than HCs (60.95±11.20 years) and the other two PD subgroups (PD-NC: 60.98±10.16 years; PD-
UC 60.63±9.76 years). In order to assess if there was a significant age-related decline in caudate 
DAT availability in our control cohort, we compared mean caudate SBRs in three subgroups of 
controls classified according to their age (50-59, 60-69, 70). No significant differences were found 
in mean caudate DAT binding across these groups (F = 2.305, p-value = 0.103). In regard to gender, 
we did not find any difference in the distribution of males and females across the three groups PD-
NC, PD-UC, PD-BC (2 = 0.221, p-value=0.895). We also did not find any significant difference 
between males and females in right, left and mean caudate DAT binding. The three PD subgroups 
did not differ significantly either in terms of disease duration or in motor symptoms as assessed 
through MDS-UPDRS III and H&Y scale scores (Table 1).  
  
  
Table 1. Baseline Cohort Demographics and Characteristics 
 
 
PD-NC = No reduced 123I-FP-CIT binding in either caudate, PD-UC = Reduced 123I-FP-CIT 
binding in one caudate only, PD-BC= bilaterally reduced caudate binding, MDS-UPDRS = 
Movement Disorder Society Unified Parkinson’s Disease Rating Scale, H&Y = Hoehn & Yahr 
scale.  
Significant difference compared to healthy controls (1p<0.05). 
  
 
 
Healthy controls 
(N=177) 
 
Mean ± SD 
PD-NC 
(N=205) 
 
Mean ± SD 
PD-UC 
(N=103) 
 
Mean ± SD 
PD-BC 
(N=89) 
 
Mean ± SD 
Age, years 60.95 ± 11.20 60.63 ± 9.76 60.98 ± 10.16 64.46 ± 8.13 
1
 
Male/Female 116/61 131/74 68/35 59/30 
Years of Education 16.11 ± 2.93 15.75 ± 2.92 15.20 ± 3.15 15.42 ± 2.97 
Duration of symptoms,  
years 
 
 
1.53 ± 2.40 1.55 ± 1.63 1.30 ± 1.50 
Duration since diagnosis,  
years 
 0.14 ± 0.40 0.20 ± 0.53 0.20 ± 0.45 
Stage of Disease (H&Y)  1.46 ± 0.50 1.56 ± 0.50 1.56 ± 0.50 
Total MDS-UPDRS Part III  
(motor) 
 19.47 ± 9.16 21.11 ± (8.69) 21.38 ± 8.89 
MOCA exam 28.23 ± 1.10 27.40 ± 2.19
1
 27.07 ± 2.63
1
 27.30 ± 2.31
1
 
GDS score 1.30 ± 2.14 2.16 ± 2.451 2.50 ± 2.431 2.61 ± 2.611 
GDS ≥ 5 11 (6.2%) 23 (11.2%)1 17 (16.5%)1 16 (18.0%)1 
RBDSQ 2.97 ± 2.4 4.35 ± 2.861 4.29 ± 2.501 2.97 ± 2.381 
Gait Index - 0.32 ± 0.80 0.32± 0.57 0.40 ± 0.69 
We then compared scores and frequencies of cognitive impairment, depression, RBD and gait 
problems between PD patients and HCs, and between PD subgroups. All the three PD subgroups 
had a significantly lower mean MoCA score compared to HCs (PD-NC: 27.40±2.19; PD-UC: 
27.07±2.63; PD-BC: 27.30±2.31; HC: 28.38±1.23; F=12.171, p<0.001). Across PD subgroups there 
were no differences in MoCA scores. For HCs, all scores were within the range for normal 
cognition (cut-off <26) as outlined in the PPMI protocol. 
In terms of clinically significant depressive features as rated by a GDS score ≥5, the frequency of 
these was higher in all PD subgroups (PD-NC: 11.2%; PD-UC: 16.5%; PD-BC: 18.0%) compared 
to HC (6.2%) (χ2=10.919, p<0.05). There were no significant differences in the frequency of 
depressive symptoms or in GDS scores between PD subgroups.  
A significant difference in mean RBDSQ score was seen between PD subgroups and HC group 
(PD-NC: 4.35±2.86; PD-UC: 4.29±2.50; PD-BC: 5.02±3.18; HC: 2.97±2.38; F=14.152 p<0.001). 
There was no significant difference between PD subgroups in terms of RBD score. 
There was no difference in self-reported gait impairment as measured by the gait index between the 
PD subgroups at baseline (H=3.924, p=0.141). 
No significant correlations were found between mean caudate 123I-FP-CIT binding and cognitive, 
mood, RBD and gait impairment ratings at baseline. 
 
Follow-Up 
Complete four-year clinical assessments were available for 323 PD patients and SPECT imaging for 
267. Follow-up clinical data were available for 151 HCs. Given the smaller PD sample at follow-
up, we compared the variables of gender, age, MoCA scores, GDS scores, RBDSQ scores and 
caudate SBRs between patients with and without available data at follow-up in order to check 
whether the follow-up cohort was representative of the baseline one. We did not find significant 
differences in these variables (Supplementary table 3). 
We then compared ratings and frequencies of cognitive impairment, depressive features, RBD and 
gait problems at the four-year follow-up among the three PD subgroups as classified at baseline 
according to their caudate SBRs. Since age and mean putamen SBR at baseline were significantly 
different across the three groups we adjusted the comparisons of continuous scores for these 
variables. Finally, we analysed the occurrence of caudate dysfunction at follow-up and the 
conversion to atypical parkinsonism. 
 
Cognitive impairment 
At four-year follow-up, MoCA scores were significantly different across PD subgroups: the PD-BC 
group had significantly lower MoCA scores compared to the PD-NC group (25.054.32 vs 
26.933.06, p<0.001) and to the PD-UC group (25.054.32 vs 27.163.21, p<0.001) (Figure 2A). 
After adjusting for age, years of education and baseline mean putamen SBR, these differences 
retained statistical significance. We further analysed the relative contributions of baseline caudate 
and putamen to MoCA scores by carrying out a univariate analysis holding baseline caudate and 
putamen SBRs as covariates: only caudate SBR was significantly associated with MoCA scores 
(B=1.522, p<0.01; putamen: B=-0.747, p=0.483). 
Furthermore, cognitive impairment as determined by the investigator based on the clinical 
interview, the presence of significant functional impairment, and review of neuropsychological 
testing, was much more common in the whole cohort of PD patients compared to HCs (21.8% vs 
5%, p<0.001). Across the three PD subgroups, the PD-BC patients were significantly more likely to 
develop cognitive impairment (42.3%, χ2=23.04, p<0.001) compared to PD-UC patients (16.7%) 
and PD-NC (15.1%). 
 
Mood disorders 
At four-year follow-up, the PD-BC group showed significantly higher GDS scores compared to PD-
NC after adjusting for age and mean putamen SBR (3.403.01 vs 2.252.63, p<0.05); no significant 
differences were observed between PD-BC and PD-UC groups and between PD-NC and PD-UC 
groups (Figure 2B). Again, we conducted a GLM univariate analysis in order to test whether 
baseline caudate and putamen SBRs were associated with GDS scores: only caudate binding was 
significantly associated with GDS scores (B=-0.999, p<0.05; putamen: B=0.532, p=0.544). 
In terms of clinically significant depression, the PD-BC group had a higher frequency compared to 
the PD-NC group (29.6% vs 10.8%, χ2=12.67, p<0.001) but the frequency in the PD-UC group 
(21.2%) did not differ significantly from that of the other two groups. 
 
RBD 
At follow-up, there was no significant difference in RBD scores between PD subgroups. 
 
Gait impairment 
The PD-BC group showed more severe gait impairment compared to the PD-NC group (mean rank 
135.31 vs 112.02, U=4735, p<0.001) and to the PD-UC group (mean rank 86.57 vs 72.75, U=2516, 
p<0.05). No significant differences were found between PD-NC and PD-UC (Figure 2C). 
 
Progression of Caudate involvement and conversion to atypical parkinsonism 
Of 267 patients with SPECT imaging available at four-year follow-up, at baseline 134 were 
classified as PD-NC (50.2%), 74 as PD-UC (27.7%) and 59 PD-BC (22.1%). After four years, 
64.3% of the baseline PD-NC group progressed to have either unilateral or bilateral caudate 
involvement; of the baseline PD-UC group, 78.4% progressed to a bilateral involvement. Overall, at 
follow-up, 83.9% of the population showed significantly reduced caudate dopamine transporter 
availability (unilateral 22.5%, bilateral 61.4%), while 16.1% still had a bilateral caudate SBR within 
-2 SDs of the controls’ mean (Table 2 and Figure 1B).  
 Table 2. Degree of caudate involvement in 267 patients with an available DATscan at four-year 
follow-up and relationship to original PD Subgroups. 
Baseline PD 
Subgroups 
(n=267) 
No Caudate 
involvement at 
4 years 
 
 
(n, %) 
Unilateral 
caudate 
involvement at 
4 years  
 
(n, %) 
  
Bilateral 
Caudate 
involvement at 
4 years 
  
(n, %) 
Total number 
of patients  
PD-NC Group 
(n, %) 
43 (32.1%) 44 (32.8%) 47 (31.5%) 134  
PD-UC Group 
(n, %) 
- 16 (21.6%) 58 (78.4%) 74 
PD-BC Group 
(n, %) 
- - 59 (100%) 59 
Total 
(n, %) 
43 (16.1%) 60 (22.5%) 164 (61.4%) 267 
PD-NC = No reduced 123I-FP-CIT binding in either caudate, PD-UC = Reduced 123I-FP-CIT 
binding in one caudate only, PD-BC = bilaterally reduced caudate binding. 
Percentages and total number of patients are relative to each row. 
 
 
The percentage of decline in caudate 123I-FP-CIT binding from baseline to follow-up was similar in 
the three groups (PD-NC=-24.5±13.0%, PD-UC=-23.8±16.4%, PD-BC=-25.1±17.2%; F=1.38, 
p=0.253). In the whole PD cohort the rates of decline in the four nuclei analysed were: right 
putamen (mean %  SD) 28.3625.94%; left putamen: 28.2827.67%; right caudate: 
24.6417.84%; left caudate: 25.0919.09%. 
Of the eight patients whose diagnosis changed to an atypical parkinsonism, at baseline six presented 
with bilaterally reduced caudate (three with MSA, three with DLB), while two had a bilaterally 
normal caudate SBR (one with MSA, one with CBD; their follow-up SPECT scans were not 
available). Baseline caudate mean SBR of these eight patients were significantly lower than the 
remaining patients (U=722.5, p<0.01); however, individual values overlapped with idiopathic PD 
patients (data not shown). 
 DISCUSSION 
In this longitudinal study, we analysed the occurrence of significant early caudate dopaminergic 
dysfunction, as defined by 123I-FP-CIT SBR below -2 SDs compared to the controls’ mean, in the 
large PPMI cohort of recently diagnosed PD patients. Furthermore, we studied the association 
between this early caudate dopamine transporter loss and the presence or subsequent development 
of cognitive impairment, depressive features, RBD and gait problems. Unlike previous studies, we 
provided a clinically viable method to define patients at risk of developing such symptoms. In fact, 
software for semiquantitative analysis of DAT-SPECT to estimate DAT availability in striatal 
subregions (i.e. putamen and caudate) are now commercially available and already adopted in many 
Nuclear Medicine Units. The assessment of the occurrence of early caudate dysfunction as 
described in this paper can therefore be easily performed in clinical settings and could serve as a 
risk marker for worse disease progression. 
In this study, we have used two standard deviations below the mean of the control population as the 
threshold to discriminate between normal or abnormal DAT availability of the caudate. DAT 
availability declines with age and our control population is slightly younger than the PD-BC group. 
Therefore, in order to assess if there was a significant age-related decline in caudate DAT 
availability in our control cohort, we compared mean caudate SBRs in three subgroups of controls 
classified according to their age (50-59, 60-69, 70). No significant differences were found in mean 
caudate DAT binding across these groups, suggesting that age-related decline of caudate binding in 
our cohort is minimal. 
Previous neuroimaging and pathophysiologic studies on striatal dopamine loss have shown uneven 
patterns of dopamine depletion in the basal ganglia.14–16 This has led to the concept of a posterior-
to-anterior gradient in early PD, with an asymmetric reduced striatal binding in the posterior 
putamen and relative preservation in the head of caudate. In this study we observed baseline 
unilateral or bilateral caudate dopaminergic dysfunction, reflected by a reduced 123I-FP-CIT binding 
<-2 SDs compared to controls, in nearly half (48.4%) of this early, untreated PD cohort.  This 
finding indicates that early caudate dopaminergic dysfunction is not uncommon in PD patients at 
the onset of parkinsonian symptoms, as opposed to what was previously thought.  Patients with 
unilateral and bilateral caudate involvement had a significantly reduced putamen 123I-FP-CIT 
binding compared to patients with no caudate dysfunction; however, the caudate/putamen ratio was 
not significantly different across PD subgroups, suggesting that the posterior-to-anterior gradient of 
dopaminergic loss is substantially preserved in all patients with PD.   
At follow-up, the majority of patients (61.4%) showed significantly reduced DAT availability in 
both caudate nuclei, and 22.5% had significant reduction in one caudate only. Only 16.1% of 
patients retained normal caudate 123I-FP-CIT uptake bilaterally. These findings are in keeping with 
previous studies that have demonstrated similar caudate and putaminal involvement in patients with 
longer disease duration.17,18   
Our results did not show a significant difference between the three PD subgroups, defined by the 
level of caudate dysfunction, on baseline assessments of cognition, mood or gait but only found a 
difference between PD subgroups with these measures at the four-year follow-up. It is likely that 
baseline caudate dopaminergic deficits are not severe enough to cause marked impairment in either 
cognition, mood or gait but later predispose to such impairments, possibly in combination with 
other neurotransmitter systems dysfunction. Indeed, we interestingly found that this early, absolute 
significant reduction of caudate signal on 123I-FP-CIT SPECT compared to controls at the time of 
clinical diagnosis is associated with worse outcomes in regard to cognitive impairment, affective 
symptoms and gait problems at the four-year follow-up.  
Several SPECT studies using dopaminergic tracers have proposed a role for caudate dysfunction in 
cognitive impairment associated with PD.3,4,24,25 Furthermore, three studies have reported early 
caudate dopaminergic dysfunction as a predictor for future cognitive impairment.5–7 Our analysis 
showed that PD patients with baseline bilateral caudate DAT binding reductions, but not unilateral 
reductions, are at greater risk of developing cognitive impairment and having lower MoCA scores 
regardless of their putamen DAT availability, age and years of education. Therefore, in comparison 
with the previously mentioned studies, we propose a practical approach that could be used in the 
clinical practice at time of diagnosis to determine which patients are at increased risk of developing 
cognitive problems in a near future. 
Depression is highly prevalent in PD with rates as high as 40%.26 The aetiology of depression has 
been attributed to deficits, with varying degrees, in the dopaminergic, serotonergic, cholinergic and 
noradrenergic pathways.27 Several neuroimaging studies have shown an association between 
reduced DAT availability in the striatum and depressive symptoms.28–30 One study demonstrated a 
negative  association between right caudate nucleus 123I-FP-CIT  binding and the severity of 
depressive symptoms.8 Our study suggests that early bilateral caudate dopaminergic dysfunction is 
associated with an increased frequency of clinically significant depression and to worse depressive 
symptoms, regardless of age and mean putamen SBR. Therefore, our results concur with other 
studies and provide further evidence that depressive symptoms in PD patients may be associated 
with dopaminergic denervation of the caudate. Again, we provided a clinical neuroimaging marker 
to determine which patients are at increased risk of developing worse depressive symptoms. 
Our study also indicated that early bilateral caudate involvement may predispose to future 
development of self-reported gait impairment. A previous PET study has demonstrated substantial 
caudate nucleus dopaminergic denervation in PD patients with gait difficulty which was 
predominantly associated with the right caudate.31 
We did not identify significant differences in RBDSQ scores across the three groups of patients at 
baseline or at the four-year follow-up. Although one study found lower DAT availability in the 
caudate nucleus of PD patients with RBD compared to those without RBD,9 it is plausible that a 
more extensive network involving other neurotransmitter systems, i.e. the cholinergic pathways,32 
are responsible for these symptoms. Furthermore, while the RBD screening questionnaire is a valid 
and widely used tool to assess RBD symptoms, only polysomnography, which was not performed 
in the PPMI study, could have provided a complete evaluation of RBD manifestations. 
Eight patients initially diagnosed with idiopathic PD had their diagnosis switched to an atypical 
parkinsonism (MSA or CBD) or to DLB at the four-year follow-up. These eight patients showed 
caudate mean SBR significantly lower than idiopathic PD patients; however individual values 
overlapped between the two groups. This is in line with previous studies that have demonstrated 
that in atypical parkinsonisms 123I-FP-CIT SPECT generally shows lower striatum uptake and 
different uptake patterns but is unable to accurately distinguish those syndromes from idiopathic 
PD.33,34 
 
A number of limitations should be addressed. The smaller sample size of 323 patients with clinical 
assessments and 267 with SPECT scan at follow-up; however, these are still relatively considerable 
numbers. In order to test whether the baseline and follow-up cohorts were similar, we verified that 
age, gender, MoCA scores, GDS scores, RBDSQ scores and caudate SBR at baseline were not 
significantly different between patients included and excluded from the follow-up analysis 
(Supplementary table 1). The clinical follow-up analysis only included the imaging variables of 
caudate and putamen DAT availability; the symptoms analysed might presumably be caused by 
extensive networks involving more than one neurotransmitter system; therefore, future multitracer 
studies may be necessary to confirm and further examine our results. Where appropriate, i.e. for 
cognitive impairment and depressive symptoms scales scores, we corrected the analysis for the 
known variables of putamen specific binding ratio, age and years of education. The gait index 
variable was not normally distributed; therefore, we were unable to carry out a corrected GLM as 
for the other scales ratings. 
 
CONCLUSION  
In this study we have demonstrated a high frequency of early caudate dopaminergic dysfunction in 
recently diagnosed PD patients. Furthermore, our findings suggest that caudate quantification of 
DAT availability shortly after diagnosis may have an important role in identifying patients at risk of 
clinical progression to cognitive impairment, depression and gait problems in the near future. In 
fact, early bilateral 123I-FP-CIT caudate uptake below -2 SDs of the controls’ mean may be a valid 
indicator of more rapid onset of such symptoms. This approach might allow better prediction of 
disease course for patients with early PD and could also provide the potential to stratify cases for 
early targeted disease-modifying therapies. 
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FIGURES 
Figure 1. Pie chart representing the three groups of patients at baseline (A) and follow up (B) 
classified according to their baseline caudate 123I-FP-CIT SPECT binding compared to healthy 
controls. 
 
 
 
 
 
 
 
 
 
 
Patients with Parkinson’s disease (baseline, n = 397; follow-up, n = 267) were categorized into 
three groups based on their baseline caudate specific binding ratios compared to healthy controls: 
no reduced 123I-FP-CIT binding in either caudate (PD-NC); 123I-FP-CIT caudate binding reduced 
below -2 SDs of the controls’ mean in one caudate only (PD-UC); 123I-FP-CIT caudate binding 
bilaterally reduced below -2 SDs of controls’ mean (PD-BC). The percentage of each subgroup in 
the PD cohort is displayed on the corresponding pie slice.  
 
 
  
Figure 2. Boxplots showing differences in outcomes in PD subgroups (n = 323) at the four-year 
follow up; (A) Montreal Cognitive Assessment score (MoCA), (B) Geriatric Depression Score 
(GDS) and (C) Gait Index score.  
 
 
 
 
 
 
 
 
 
PD-NC: Parkinson’s disease patients with no reduced caudate 123I-FP-CIT binding compared to the 
controls’ mean at baseline. PD-UC: Parkinson’s disease patients with reduced baseline caudate 123I-
FP-CIT binding below -2 SDs of the controls’ mean in one caudate only. PD-BC: Parkinson’s 
disease patients with reduced baseline caudate 123I-FP-CIT binding below -2 SDs of the controls’ 
mean in both caudate nuclei. A: Bar charts representing mean MoCA scores with 95% CIs at the 
four-year follow-up. B: Bar charts representing mean GDS scores with 95% CIs at the four-year 
follow-up. C: Boxes and whiskers representing distributions of the gait index scores (product of 
MDS-UPDRS II sub-items 2.12 and 2.13) at the four-year follow-up. Boxes: 25th to 75th percentiles; 
whiskers 95th percentile. *p<0.05, **p<0.001. 
 


SUPPLEMENTARY MATERIAL 
 
SECTION 1 – PPMI cognitive categorization 
The following cognitive tests assessing memory, visuospatial function, processing speed-attention, 
executive function and semantic fluency were administered to each patient as part of the PPMI 
study: Hopkins Verbal Learning Test-Revised (HLVT-R), Benton Judgment of Line Orientation 
(JOLO) 15-item (split-half) version, Symbol-Digit Modalities Test (SDMT), Letter-Number 
Sequencing (LNS) and semantic fluency tests (animals, vegetables and fruits).  
The Cognitive Categorization assessment was used to make a determination of Parkinson Disease 
Dementia (PDD) and PD with mild cognitive impairment (PD-MCI).  Information for this 
assessment was provided through a combination of responses from the subject or other informant, 
the Investigator’s judgment, and results from the cognitive testing covering the four cognitive 
domains mentioned above. 
The determination of PDD was made on the following factors: (i) History of cognitive decline 
determined by the investigator based on information from the patient, other informant (spouse, 
family member or friend) and the investigator’s judgment (The investigator reports the presence of 
cognitive decline [Yes/No] based on clinical evaluation of attention, memory, orientation, executive 
abilities, praxis and language and the presence of functional impairment compared to premorbid 
state; this determination is made prior to or independent from review of neuropsychological test 
scores/results); (ii) Cognitive impairment defined as at least 1 test score (out of 6 scores) from at 
least 2 domains (out of 4 domains) >1.5 SD below the standardized mean; (iii) Functional limitation 
as a result of cognitive impairment (IADLs). 
The determination of PD-MCI was made based on the following factors: (i) Cognitive complaint by 
either the patient or informant (spouse, family member or friend); (ii) Cognitive impairment defined 
as at least 2 test scores (out of 6 scores) from at least 1 domain (out of 4 domains) >1.0 SD below 
the standardized mean; (iii) No functional impairment as a result of cognitive impairment (IADLs). 
 
SECTION 2 – PPMI DAT imaging protocol 
Imaging site set up. All PPMI imaging centres were visited for technical site evaluation and set up 
which involved performing a SPECT acquisition on an anthropomorphic striatal phantom filled 
with 123Ioflupane on the same camera with the same parameters and collimators as the subsequent 
patients imaged in the study. This procedure was used to optimize and standardize the 
reconstruction and filtration of the SPECT images across the different imaging centers.  
123I-FP-CIT SPECT procedure. Before the 123I-FP-CIT injection, subjects were pre-treated with 
stable iodine (10 drops of a saturated solution of potassium iodide) to reduce the uptake of 123I-FP-
CIT by the thyroid. Subjects were injected with 3-5 mCi (111–185 MBq) of 123I-FP-CIT. Within a 4 
hour (+/- 30 minute) window following the injection, subjects underwent SPECT imaging on the 
camera. Raw SPECT data were acquired into a 128x128 matrix stepping each 3° for a total of 120 
(or 4° for a total of 90) projections in a window centred on 159±10 KeV with a total scan duration 
of 30-45 min.  
Processing and analysis. 123I-FP-CIT SPECT imaging acquired at each PPMI imaging center were 
sent to Institute for Neurodegenerative Disorders, New Haven, Connecticut for processing and 
calculation of SBRs. SPECT raw projection data were imported to a HERMES (Hermes Medical 
Solutions, Skeppsbron 44, 111 30 Stockholm, Sweden) system for iterative (HOSEM) 
reconstruction. This was done for all imaging centers to ensure consistency of the reconstructions. 
Iterative reconstruction was done without any filtering applied. The HOSEM reconstructed files 
were then transferred to PMOD (PMOD Technologies, Zurich, Switzerland) for subsequent 
processing. Attenuation correction ellipses where drawn on the images and a Chang 0 attenuation 
correction was applied utilizing a site specific mu that was empirically derived from phantom data 
acquired during site initiation for the trial. Once attenuation correction was completed, a standard 
Gaussian 3D 6.0 mm filter was applied. These files were then normalized to standard Montreal 
Neurologic Institute (MNI) space so that all scans were in the same anatomical alignment. Next the 
transaxial slice with the highest striatal uptake was identified and the 8 hottest striatal slices around 
it were averaged in to generate a single slice image. Regions of interest (ROI) were then placed on 
the of left and right caudate, the left and right putamen, and the occipital cortex (reference tissue). 
Count densities for each region were extracted and used to calculate striatal binding ratios (SBRs) 
for each of the 4 striatal regions. SBR were calculated as (target region/reference region)-1.  
  
SUPPLEMENTARY TABLES 
 
Supplementary table 1. Distribution of caudate and putamen 123I-FP-CIT binding across PD 
patients compared to the controls’ mean (caudate: mean ± SD = 2.56 ± 0.60; putamen: mean ± SD = 
2.14 ± 0.55).  
 
 Within -2 SD  Unilateral reduction Bilataral reduction 
Caudate, n  205 103 89 
Putamen, n 25* 120 252 
Unilateral reduction: one side < -2 SDs of the controls’ mean. Bilateral reduction: both sides < -2 
SDs of the controls’ mean. 
 
 
Supplementary table 2. Reciprocal distribution of caudate and putamen 123I-FP-CIT binding across 
PD patients as classified in comparison to the controls’ mean (caudate: mean ± SD = 2.56 ± 0.59; 
putamen: mean ± SD = 2.14 ± 0.55).  
 
 Caudate, SDs with respect to HCs’ mean 
Within -2 SD, n 
 
Unilateral 
reduction, < -2 
SDs, n 
Bilateral 
reduction, < - 2 
SDs, n 
 
Putamen, 
 
SDs with 
respect 
to HCs’ 
mean 
 
Within -2 SD, n 
 
 
25* 
 
0 
 
0 
 
Unilateral reduction < -2 
SDs, n 
 
91 
 
28 
 
1 
 
Bilateral reduction < - 2 
SDs, n 
 
89 
 
75 
 
88 
 
 
* All these patients had an abnormal pattern of putaminal uptake on DAT SPECT visual assessment 
compatible with the presence of nigrostriatal hypofunction. Their mean ± SD reduction in the most 
affected putamen compared to healthy controls [((mean putamen in HCs – most affected putamen 
PD) / mean putamen in HCs)*100] was 63.61 ± 30.64%.  
  
Supplementary Table 3. Comparison of baseline clinical variables between patients with and 
without available data at follow up. 
 
 Available (n = 323) Not available (n =74) P-value 
Age  
(years, mean ± SD) 
61.26 ± 9.88 63.49 ± 8.87 0.119 
Gender  
(M/F) 
173/94 85/45 0.591 
MoCA score  
(mean ± SD) 
27.28 ± 2.31 27.34 ± 2.46 0.852 
GDS score  
(mean ± SD) 
2.26 ± 2.40 2.76 ± 2.81 0.121 
RBDSQ score  
(mean ± SD) 
4.43 ± 2.79 4.75 ± 3.16 0.437 
Caudate SBR  
(mean ± SD) 
1.99 ± 0.52 
(n=267) 
2.00 ± 0.64 
(n=130) 
0.934 
An independent t-test was used in order to assess differences between groups in age, MoCA score, 
GDS score, RBDSQ score and caudate SBR. A Fisher exact chi-square test was used in order to 
assess differences in gender between groups. 
MoCA: Montreal Cognitive Assessment 
GDS: geriatric depression scale 
RBDSQ: REM sleep behavior disorder questionnaire 
SBR: specific binding ratio 
 
